Medicare Coverage Boosts Novo Nordisk's Obesity Push Amid MFN Pricing, Oral Wegovy Launch

Medicare coverage opens a critical window for Novo Nordisk's obesity strategy

Novo Nordisk is positioning itself to expand U.S. access to GLP‑1 obesity treatments as Medicare prepares to begin coverage later this year under the most‑favored‑nation (MFN) pricing deals the company struck with the White House. Chief Executive Mike Doustdar says the Danish drugmaker aims to capture about 15 million new patients initially, a subset of roughly 67 million Americans on Medicare, even as some outside experts put the Medicare population living with obesity at 20 million to 30 million. The company expects Medicare coverage, together with the launch of its new oral Wegovy pill, to gradually lift prescription volumes and offset lower U.S. prices from the MFN agreement.

Novo stresses that uptake will be gradual and contingent on several factors, including payer behavior, physician acceptance and supply reliability. Doustdar highlights differentiation of the oral pill versus rivals, physician education and demonstration of real‑world outcomes as central to accelerating adoption. He also notes ongoing negotiations with the government over the exact month and week coverage opens, signalling uncertainty about the timing of the volume boost the company plans to rely on.

Competition and market dynamics shape Novo’s approach as it seeks to regain share lost to Eli Lilly and lower‑cost compounded alternatives. Lilly holds a leading share of the U.S. obesity and diabetes GLP‑1 market while Novo points to the oral Wegovy’s lead over Lilly’s orforglipron — which is expected to seek FDA approval in the second quarter — as a path to narrow the gap. Novo also warns that cheaper compounded semaglutide copycats and commercial payer practices could complicate uptake, making supply, safety and regulatory compliance key elements of its 2026 strategy.

Legal battle over compounded GLP‑1 pills

Novo is intensifying legal action against telehealth and compounders it says are distributing unapproved semaglutide knockoffs, filing suit against Hims & Hers and other compounders. CEO Doustdar warns that broad compounding using unknown raw‑material sources risks patient safety and undermines trust, while defendants frame the disputes as access issues and accuse Novo of targeting patients who rely on compounded medicines.

Federal drug‑pricing platform lists Novo medicines

The Trump administration is also rolling out a consumer‑facing drug pricing site, TrumpRx.gov, that lists discounted prices for 40 medicines from five manufacturers, including Novo Nordisk. Officials say the platform aims to match MFN pricing and will be updated over time, though clinicians caution its initial scope and interaction with existing insurance formularies may limit immediate impact.